Teva Pharmaceutical Industries (NYSE:TEVA) Reaches New 1-Year High Following Analyst Upgrade

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) shares reached a new 52-week high on Monday after The Goldman Sachs Group raised their price target on the stock from $28.00 to $31.00. The Goldman Sachs Group currently has a buy rating on the stock. Teva Pharmaceutical Industries traded as high as $28.74 and last traded at $28.1090, with a volume of 733080 shares. The stock had previously closed at $28.46.

Several other analysts have also weighed in on the stock. UBS Group lifted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, October 8th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 11th. JPMorgan Chase & Co. raised their target price on Teva Pharmaceutical Industries from $26.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Finally, Scotiabank began coverage on Teva Pharmaceutical Industries in a research note on Friday. They issued a “sector outperform” rating and a $35.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.88.

Insider Activity at Teva Pharmaceutical Industries

In other news, Director Roberto Mignone sold 200,000 shares of the business’s stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $24.11, for a total value of $4,822,000.00. Following the transaction, the director directly owned 495,000 shares of the company’s stock, valued at $11,934,450. The trade was a 28.78% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.55% of the stock is owned by insiders.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of TEVA. Cetera Investment Advisers grew its holdings in shares of Teva Pharmaceutical Industries by 2.5% during the first quarter. Cetera Investment Advisers now owns 54,430 shares of the company’s stock worth $837,000 after purchasing an additional 1,325 shares during the last quarter. LPL Financial LLC lifted its position in Teva Pharmaceutical Industries by 5.5% during the 1st quarter. LPL Financial LLC now owns 213,280 shares of the company’s stock worth $3,278,000 after buying an additional 11,029 shares in the last quarter. US Bancorp DE grew its holdings in Teva Pharmaceutical Industries by 6.5% during the 1st quarter. US Bancorp DE now owns 10,812 shares of the company’s stock worth $166,000 after acquiring an additional 656 shares during the last quarter. PNC Financial Services Group Inc. increased its position in Teva Pharmaceutical Industries by 2.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 59,647 shares of the company’s stock valued at $917,000 after acquiring an additional 1,578 shares in the last quarter. Finally, Blair William & Co. IL raised its stake in shares of Teva Pharmaceutical Industries by 67.2% in the first quarter. Blair William & Co. IL now owns 18,782 shares of the company’s stock worth $289,000 after acquiring an additional 7,550 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

The company has a quick ratio of 0.82, a current ratio of 1.11 and a debt-to-equity ratio of 2.31. The stock’s 50-day moving average price is $22.48 and its 200-day moving average price is $19.20. The company has a market capitalization of $32.43 billion, a price-to-earnings ratio of 47.11, a price-to-earnings-growth ratio of 1.53 and a beta of 0.66.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.